D
Dauntlessph
–/10Traction
The startup develops a non-injectable somatostatin analog that provides an alternative to traditional injectable growth hormone inhibitors used in the treatment of acromegaly and neuroendocrine tumors. This therapeutic approach offers patients a non-invasive option for short-acting therapy, enhancing treatment accessibility and comfort.
San Diego, United States · HQ
- Biotechnology
Updated 4 months ago
Funding
Funding not disclosed
SofinnovaNo round attributed
- sofinnova.com (opens in a new tab)investor website
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a non-injectable somatostatin analog that provides an alternative to traditional injectable growth hormone inhibitors used in the treatment of acromegaly and neuroendocrine tumors. This therapeutic approach offers patients a non-invasive option for short-acting therapy, enhancing treatment accessibility and comfort.